CREST Study Reports 12-Month Ocular Safety in Bio-Interventional Uveoscleral Outflow Enhancement
A multicenter real-world cohort of 395 eyes suggests that bio-interventional uveoscleral outflow enhancement can be performed with a favorable 12-month ocular safety profile in open-angle glaucoma. The CREST study followed adults treated with acellular scleral allograft spacers, either as a standalone procedure or combined with phacoemulsification, and captured adverse events prospectively at prespecified visits. The central clinical question was not whether intraocular pressure could fall, but whether altering uveoscleral outflow through a bio-interventional scaffold could do so without provoking corneal, infectious, or implant-related harm over the first postoperative year.
The dataset is sizable for an early safety readout. Mean age was 72.8 years, 52% of participants were female, and the cohort split into 267 eyes treated with cataract surgery plus the spacer and 128 eyes treated with the spacer alone. In a procedure that works by augmenting the uveoscleral pathway, postoperative safety must be viewed through two lenses at once: the implant’s interaction with the anterior segment and the known physiologic stress of concomitant cataract surgery. The first-year findings suggest that the allograft itself did not generate an obvious signal for catastrophic corneal failure or intraocular infection.
Pressure Reduction Came With Modest Medication Relief
The efficacy signals were encouraging even though this analysis focused on safety. Medicated intraocular pressure declined from 19.1 mmHg to 14.5 mmHg, with a statistically significant reduction, and the number of glaucoma medications fell from 1.9 to 1.2. Forty-two percent of eyes became medication-free. In glaucoma care, medication reduction is not a cosmetic endpoint; fewer drops can mean fewer adherence failures, less ocular surface toxicity, and less chronic exposure to preservative-related irritation.
The pressure effect is biologically coherent. By facilitating aqueous humor egress through the uveoscleral route, the spacer may reduce reliance on the trabecular outflow system and lower the pressure burden that drives optic nerve injury. For many patients, the practical aim is simple: preserve pressure control while reducing daily medication load and avoiding the risks that can accompany more invasive filtration surgery.
Serious Ocular Events Were Uncommon and Mostly Managed Without Surgery
Safety events did occur, but the profile remained largely limited and clinically manageable. Sustained intraocular pressure elevation, defined as a rise of at least 10 mmHg beyond 30 days, occurred in 34 eyes, representing 8.6% of the cohort. Best-corrected visual acuity loss of at least two lines occurred in 15 eyes, or 3.8%. Hyphema greater than 2 mm was recorded in 6 eyes, and hypotony in just 1 eye. Serious events were documented in 12 eyes, equal to 3.0%.
One episode deserves attention because it speaks directly to device behavior rather than to postoperative inflammation alone. Two allograft spacers entered the anterior chamber in one eye and were successfully repositioned intraoperatively. In a procedure that depends on precise anatomic placement, migration is the kind of mechanical complication surgeons watch for closely. The fact that the event was corrected during surgery rather than cascading into a more severe consequence is reassuring, but it also keeps the conversation grounded in procedural execution as much as in material safety.
There were no reports of endothelial decompensation, endophthalmitis, or sympathetic ophthalmia. Each of those outcomes would carry a very different clinical weight. Endophthalmitis would raise alarms about contamination or breach of sterile barriers. Sympathetic ophthalmia, though rare, would introduce a severe bilateral inflammatory concern. Endothelial decompensation would directly threaten corneal clarity and visual function. Their absence through 12 months is the strongest safety signal in the study.
Endothelial Cell Loss Appeared More Consistent With Cataract Surgery Than the Allograft
Specular microscopy was available in a subgroup of 91 eyes with paired data. In that subset, endothelial cell density fell by 6.5%, with the confidence interval suggesting a measurable decline. The investigators interpreted the loss as tracking with concurrent cataract surgery rather than with the allograft spacer itself, although the subgroup was small. That distinction is clinically important because the corneal endothelium has limited regenerative capacity, and any persistent attrition after an anterior segment procedure can narrow the margin of safety for future interventions.
The data do not prove that the implant is irrelevant to endothelial change; they indicate that the observed decline aligns more naturally with the stress profile of phacoemulsification. Ultrasound energy, fluidics, and surgical manipulation around the anterior chamber are established contributors to endothelial cell loss. In this cohort, the allograft did not emerge as a clear independent driver of corneal decompensation during the first year.
What This Means for Surgical Glaucoma Practice
The CREST findings place bio-interventional uveoscleral outflow enhancement in a practical middle ground between traditional angle-based procedures and more aggressive filtration operations. The 12-month horizon is long enough to detect many early anatomic and inflammatory complications, but not long enough to settle the question of durability or delayed endothelial toxicity. The concluding comparison in the abstract is especially telling: follow-up remains shorter than the interval over which an earlier supraciliary microstent diverged from controls. In other words, the current safety profile is encouraging, but the real test may come later.
For surgeons, the early takeaway is that the procedure can reduce pressure and medication burden while keeping the cornea, the posterior segment, and the fellow eye free of the most feared complications over one year. For patients, the value proposition rests on a balance between added anatomic intervention and the possibility of simplified glaucoma control. The absence of major infectious or corneal events will matter most to clinicians deciding whether the risk profile is acceptable for broader use.
The remaining unknown is durability. Twelve months can show whether the surgery is tolerated; it cannot fully answer how the implant behaves over several years, whether migration risk changes with time, or whether endothelial attrition accumulates in a way that matters clinically. Longer follow-up from CREST will determine whether the early safety pattern persists or gives way to a more limited indication set.
- • ClinicalTrials.gov Trial Protocol (NCT05506423): https://clinicaltrials.gov/study/NCT05506423
- • medRxiv DOI (10.64898/2026.11.12.26367928): https://doi.org/10.64898/2026.11.12.26367928